{"id":"W4388534086","doi":"10.1016/j.annonc.2023.10.129","title":"Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline","year":2023,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Foundation Medicine; Genentech; INCLIVA Instituto de Investigación Sanitaria; Servier; European Society for Medical Oncology; Astellas Pharma; Sierra Oncology; Incyte; Sociedad Española de Oncología Médica; BeiGene; Natera; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Les Laboratories Pierre Fabre; Amgen","keywords":"Medicine; Colorectal cancer; Bevacizumab; Internal medicine; Oncology; Oxaliplatin; Irinotecan; Guideline; Cancer; Hazard ratio; Chemotherapy regimen; Chemotherapy; Confidence interval; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003700953,0.000710435,0.001836395,0.001954666,0.002481873,0.003235068,0.002285032,0.03176204,0.01235511],"category_scores_gemma":[0.02088179,0.0007777624,0.002858269,0.001798711,0.001239257,0.001932594,0.001647628,0.02215725,0.009782024],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007391509,"about_ca_system_score_gemma":0.01887755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.05387843,"about_ca_topic_score_gemma":0.1584606,"domain_scores_codex":[0.994803,0.001336723,0.0008297747,0.0002631576,0.00207383,0.0006936029],"domain_scores_gemma":[0.9880555,0.003003853,0.001398852,0.0002732347,0.004430533,0.002838148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001892215,0.00003596609,0.0002931143,0.00005197191,0.00001299853,0.0001367035,0.00002098296,0.000059905,0.00005339862,0.0008120186,0.9908895,0.007614545],"study_design_scores_gemma":[0.0002195345,0.00003819347,0.003659774,0.0009713889,0.00006878169,0.000367587,0.00005342922,0.0002750514,0.00007502075,0.002054686,0.992178,0.00003858152],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0006138714,0.003994663,0.000529111,0.9292231,0.02528555,0.0002037149,0.002505993,0.0001239218,0.03752004],"genre_scores_gemma":[0.002983984,0.004609049,0.00300745,0.9238624,0.02619376,0.0004376181,0.002601378,0.00008398315,0.03622029],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.05387843,"threshold_uncertainty_score":0.1071296,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1360276790511177,"score_gpt":0.4430559919145119,"score_spread":0.3070283128633943,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}